Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 20-valent pneumococcal conjugate vaccine in healthy infants
2019-003305-10Phase 3
- Sponsor
- Pfizer
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing 20vPnC with 13vPnC (2 arms). Primary endpoint: Percentage of subjects with local reactions within 7 days after each dose.
02
Drugs
Prevnar 20pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2019-003305-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003305-10.